Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in The Treatment of Parenteral Nutrition Induced Liver Injury in Children
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This expanded access protocol is for infants or children with conditions preventing them from taking in enough nutrients from food and must receive nutrition intravenously. Standard intravenous nutrition contains fat emulsion made from soybean. If this fat emulsion is given over a long period of time, it can cause problems within the liver and if persistent and not addressed can even lead to severe and/or permanent injury to the liver.
It is believed that a type of fish oil blend, called Omegaven®, may be used in place of the soybean fat blend. The Omegaven® fish oil blend may greatly reduce the risk of liver injury.
Omegaven® is not approved by the Food and Drug Administration (FDA). It is only offered under an "expanded access" protocol as an alternative to the soybean fat blend.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 15 Days 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •Older than 14 days and less than 5 years of age
- •Direct bilirubin value is greater than 2 mg/dL
- •Be expected to require intravenous nutrition for at least an additional 28 days
- •Parent/legal guardian has agreed to provide consent/parental permission
排除标准
- •Patients who have a congenitally lethal condition (e.g. Trisomy 13).
- •Patients who have clinically severe bleeding not able to be managed with routine measures.
- •Patients who have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis.
- •Patients who have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves.
- •5 The parent/legal guardian is unwilling to provide consent/parental permission.
研究者
Edward Everett DO
Principal Investigator
Geisinger Clinic